TABLE 3.

Changes in geometric mean titer of neutralizing antibody to the vaccine strain

Timing	Phase II								Phase III
	MA group		HA group		MB group		HB group		MA group
	GMT (Confidence interval)	Rates of antibody rise of 4‐fold or higher (%) [Confidence interval (%)]	GMT (Confidence interval)	Rates of antibody rise of 4‐fold or higher (%) [Confidence interval (%)]	GMT (Confidence interval)	Rates of antibody rise of 4‐fold or higher (%) [Confidence interval (%)]	GMT (Confidence interval)	Rates of antibody rise of 4‐fold or higher (%) [Confidence interval (%)]	GMT (Confidence interval)	Rates of antibody rise of 4‐fold or higher (%) [Confidence interval (%)]
Number of analyzed subjects	62		61		63		60		364
Before vaccination (Day 0)	5.1 (4.9‐5.2)	－	5.1 (4.9‐5.2)	－	5.0	－	5.0	－	5.0	－
After the 1st vaccination (Day 21)	9.8 (8.0‐12.0)	27.4 (16.9‐40.2)	13.1 (10.7‐16.2)	39.3 (27.1‐52.7)	8.7 (7.3‐10.3)	20.6 (11.5‐32.7)	9.5 (7.8‐11.7)	21.7 (12.1‐34.2)	10.2 (9.5‐11.1)	27.5 (22.9‐32.4)
After the 2nd vaccination (Day 42)	234.3 (182.5‐300.7)	100.0 (94.0‐100.0)	265.2 (205.0‐343.0)	98.3 (90.9‐100.0)	171.3 (130.9‐224.1)	100.0 (94.1‐100.0)	211.1 (162.1‐274.9)	98.3 (91.1‐100.0)	301.1 (275.4‐329.2)	99.7 (98.5‐100.0)

Strain measured: A/Indonesia/05/2005(H5N1). Vaccine strain: A/Indonesia/05/2005(H5N1).Subjects analyzed: FAS.GMT: geometric mean antibody titer. Confidence interval: lower limit and upper limit of the 95% two‐sided confidence interval based on Student's t‐distribution. MA group; 3.75 μg HA + AS03. HA group; 7.5 μg HA + AS03. MB group; 3.75 μg HA + 1/2 AS03. HB group; 7.5 μg HA + 1/2 AS03.